J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in Multiple Myeloma
July 19 2019 - 07:45AM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit
on Friday said is seeking approval from the European Medicines
Agency for subcutaneous use of Darzalex in patients with multiple
myeloma.
Darzalex is currently only approved for intravenous use.
Janssen said subcutaneous Darzalex is co-formulated with
Halozyme Therapeutics Inc.'s (HALO) Enhanze drug-delivery
technology.
Janssen last week filed for U.S. Food and Drug Administration
approval for the subcutaneous formulation of Darzalex in multiple
myeloma, a cancer that forms in a type of white blood cells called
plasma cells and causes cancer cells to accumulate in the bone
marrow.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 19, 2019 07:30 ET (11:30 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Mar 2023 to Mar 2024